Skip to main content
Midas Edge

Intellia Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

NTLA$11.17-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(Amounts in thousands, except share data)

Additional · Accumulated Other · Total
Common · Paid-In · Comprehensive · Accumulated · Stockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance at December 31, 202287,103,007$9$2,420,223$(7,461)$(1,177,187)$1,235,584
Issuance of common stock through at-the-market offerings, net of issuance costs of $3764,122,824-121,870--121,870
Contingent consideration paid to Rewrite Holders567,045-24,126--24,126
Exercise of stock options385,130-6,599--6,599
Vesting of restricted stock units677,055-----
Issuance of shares under employee stock purchase plan142,097-3,929--3,929
Stock-based compensation--134,050--134,050
Other comprehensive income (loss) - unrealized gain on marketable securities---3,635-3,635
Other comprehensive income (loss) - unrealized gain on equity method investment---1,568-1,568
Net loss----(481,192)(481,192)
Balance at December 31, 202392,997,15892,710,797(2,258)(1,658,379)1,050,169
Issuance of common stock through at-the-market offerings, net of issuance costs of $2547,004,3701174,823--174,824
Exercise of stock options373,807-5,862--5,862
Vesting of restricted stock units1,433,669-----
Issuance of shares under employee stock purchase plan220,590-2,986--2,986
Stock-based compensation--154,273--154,273
Other comprehensive income (loss) - unrealized gain on marketable securities---731-731
Reclassification of other comprehensive income (loss) - equity method investment---2,132-2,132
Net loss----(519,021)(519,021)
Balance at December 31, 2024102,029,594103,048,741605(2,177,400)871,956
Issuance of common stock through at-the-market offerings, net of issuance costs of $011,790,6242128,173--128,175
Exercise of stock options87,858-722--722
Vesting of restricted stock units2,076,966-----
Issuance of shares under employee stock purchase plan332,018-2,589--2,589
Stock-based compensation--80,219--80,219
Other comprehensive income (loss) - unrealized gain on marketable securities---427-427
Net loss----(412,694)(412,694)
Balance at December 31, 2025116,317,060$12$3,260,444$1,032$(2,590,094)$671,394
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.